Pathophysiological mechanisms of liver injury in COVID‐19
AD Nardo, M Schneeweiss‐Gleixner… - Liver …, 2021 - Wiley Online Library
The recent outbreak of coronavirus disease 2019 (COVID‐19), caused by the Severe Acute
Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) has resulted in a world‐wide …
Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) has resulted in a world‐wide …
Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions
The coronavirus disease-19 pandemic (COVID-19), which appeared in China in December
2019 and rapidly spread throughout the world, has forced clinicians and scientists to take up …
2019 and rapidly spread throughout the world, has forced clinicians and scientists to take up …
[HTML][HTML] ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities
N Zamorano Cuervo, N Grandvaux - elife, 2020 - elifesciences.org
Pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes
coronavirus 19 disease (COVID-19) which presents a large spectrum of manifestations with …
coronavirus 19 disease (COVID-19) which presents a large spectrum of manifestations with …
[HTML][HTML] Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
Substantial COVID-19 research investment has been allocated to randomized clinical trials
(RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or …
(RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or …
Observational study of hydroxychloroquine in hospitalized patients with Covid-19
Background Hydroxychloroquine has been widely administered to patients with Covid-19
without robust evidence supporting its use. Methods We examined the association between …
without robust evidence supporting its use. Methods We examined the association between …
Azithromycin in the treatment of COVID-19: a review
D Echeverría-Esnal, C Martin-Ontiyuelo… - Expert review of anti …, 2021 - Taylor & Francis
Introduction SARS-CoV-2 is a novel virus that causes coronavirus disease-19 (COVID-19).
Antiviral and immunomodulatory agents have been proposed as potential treatments …
Antiviral and immunomodulatory agents have been proposed as potential treatments …
Evidence of structural protein damage and membrane lipid remodeling in red blood cells from COVID-19 patients
T Thomas, D Stefanoni, M Dzieciatkowska… - Journal of proteome …, 2020 - ACS Publications
The SARS-CoV-2 beta coronavirus is the etiological driver of COVID-19 disease, which is
primarily characterized by shortness of breath, persistent dry cough, and fever. Because they …
primarily characterized by shortness of breath, persistent dry cough, and fever. Because they …
Guillain–Barré syndrome variant occurring after SARS‐CoV‐2 vaccination
Although SARS‐CoV‐2 vaccines are very safe, we report 4 cases of the bifacial weakness
with paresthesias variant of Guillain–Barré syndrome (GBS) occurring within 3 weeks of …
with paresthesias variant of Guillain–Barré syndrome (GBS) occurring within 3 weeks of …
[HTML][HTML] Cell entry by SARS-CoV-2
Severe acute respiratory syndrome virus 2 (SARS-CoV-2) invades host cells by interacting
with receptors/coreceptors, as well as with other cofactors, via its spike (S) protein that …
with receptors/coreceptors, as well as with other cofactors, via its spike (S) protein that …
Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions
M Filosto, SC Piccinelli, S Gazzina, C Foresti… - Journal of Neurology …, 2021 - jnnp.bmj.com
Objective Single cases and small series of Guillain-Barré syndrome (GBS) have been
reported during the SARS-CoV-2 outbreak worldwide. We evaluated incidence and clinical …
reported during the SARS-CoV-2 outbreak worldwide. We evaluated incidence and clinical …